Literature DB >> 26376455

Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses.

Anna Wilkaniec1, Grzegorz A Czapski1, Agata Adamczyk1.   

Abstract

Cyclin-dependent kinase 5 (Cdk5) is involved in proper neurodevelopment and brain function and serves as a switch between neuronal survival and death. Overactivation of Cdk5 is associated with many neurodegenerative disorders such as Alzheimer's or Parkinson's diseases. It is believed that in those diseases Cdk5 may be an important link between disease-initiating factors and cell death effectors. A common hallmark of neurodegenerative disorders is incorrect folding of specific proteins, thus leading to their intra- and extracellular accumulation in the nervous system. Abnormal Cdk5 signaling contributes to dysfunction of individual proteins and has a substantial role in either direct or indirect interactions of proteins common to, and critical in, different neurodegenerative diseases. While the roles of Cdk5 in α-synuclein (ASN) - tau or β-amyloid peptide (Aβ) - tau interactions are well documented, its contribution to many other pertinent interactions, such as that of ASN with Aβ, or interactions of the Aβ - ASN - tau triad with prion proteins, did not get beyond plausible hypotheses and remains to be proven. Understanding of the exact position of Cdk5 in the deleterious feed-forward loop critical for development and progression of neurodegenerative diseases may help designing successful therapeutic strategies of several fatal neurodegenerative diseases. Cyclin-dependent kinase 5 (Cdk5) is associated with many neurodegenerative disorders such as Alzheimer's or Parkinson's diseases. It is believed that in those diseases Cdk5 may be an important factor involved in protein misfolding, toxicity and interaction. We suggest that Cdk5 may contribute to the vicious circle of neurotoxic events involved in the pathogenesis of different neurodegenerative diseases.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  Alzheimer's disease; Parkinson's disease; cyclin-dependent kinase 5; misfolded proteins; neurodegeneration

Mesh:

Substances:

Year:  2015        PMID: 26376455     DOI: 10.1111/jnc.13365

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  19 in total

Review 1.  Using the shared genetics of dystonia and ataxia to unravel their pathogenesis.

Authors:  Esther A R Nibbeling; Cathérine C S Delnooz; Tom J de Koning; Richard J Sinke; Hyder A Jinnah; Marina A J Tijssen; Dineke S Verbeek
Journal:  Neurosci Biobehav Rev       Date:  2017-01-28       Impact factor: 8.989

Review 2.  Tau-targeting therapies for Alzheimer disease.

Authors:  Erin E Congdon; Einar M Sigurdsson
Journal:  Nat Rev Neurol       Date:  2018-07       Impact factor: 42.937

3.  Activating transcription factor-4 promotes neuronal death induced by Parkinson's disease neurotoxins and α-synuclein aggregates.

Authors:  Matthew D Demmings; Elizabeth C Tennyson; Gillian N Petroff; Heather E Tarnowski-Garner; Sean P Cregan
Journal:  Cell Death Differ       Date:  2020-12-04       Impact factor: 15.828

4.  Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein.

Authors:  Giusi Manassero; Michela Guglielmotto; Raluca Zamfir; Roberta Borghi; Laura Colombo; Mario Salmona; George Perry; Patrizio Odetti; Ottavio Arancio; Elena Tamagno; Massimo Tabaton
Journal:  Aging Cell       Date:  2016-07-12       Impact factor: 9.304

Review 5.  Emerging Link between Alzheimer's Disease and Homeostatic Synaptic Plasticity.

Authors:  Sung-Soo Jang; Hee Jung Chung
Journal:  Neural Plast       Date:  2016-02-25       Impact factor: 3.599

6.  Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity.

Authors:  Anna Wilkaniec; Magdalena Gąssowska-Dobrowolska; Marcin Strawski; Agata Adamczyk; Grzegorz A Czapski
Journal:  J Neuroinflammation       Date:  2018-01-04       Impact factor: 8.322

Review 7.  Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.

Authors:  Xi-Lin Wu; Juan Piña-Crespo; Yun-Wu Zhang; Xiao-Chun Chen; Hua-Xi Xu
Journal:  Chin Med J (Engl)       Date:  2017-12-20       Impact factor: 2.628

8.  Genetic risk for schizophrenia and psychosis in Alzheimer disease.

Authors:  M A A DeMichele-Sweet; E A Weamer; L Klei; D T Vrana; D J Hollingshead; H J Seltman; R Sims; T Foroud; I Hernandez; S Moreno-Grau; L Tárraga; M Boada; A Ruiz; J Williams; R Mayeux; O L Lopez; E L Sibille; M I Kamboh; B Devlin; R A Sweet
Journal:  Mol Psychiatry       Date:  2017-05-02       Impact factor: 15.992

9.  Using the Gene Ontology to Annotate Key Players in Parkinson's Disease.

Authors:  R E Foulger; P Denny; J Hardy; M J Martin; T Sawford; R C Lovering
Journal:  Neuroinformatics       Date:  2016-07

10.  P2X7 receptor-pannexin 1 interaction mediates extracellular alpha-synuclein-induced ATP release in neuroblastoma SH-SY5Y cells.

Authors:  Anna Wilkaniec; Magdalena Gąssowska; Grzegorz A Czapski; Magdalena Cieślik; Grzegorz Sulkowski; Agata Adamczyk
Journal:  Purinergic Signal       Date:  2017-05-17       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.